Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESK-001 in Moderate to Severe Plaque Psoriasis (ONWARD2)
NCT06588738Phase 3Completed
- Sponsor
- Alumis Inc.
- Start
- Aug 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of envudeucitinib in plaque psoriasis (3 arms), sponsored by Alumis Inc. Primary endpoints: Psoriasis Area and Severity Index 75% Reduction at 16 weeks and Static Physician's Global Assessment at 16 weeks. Started Aug 2024; status: completed.
02
Drugs
envudeucitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06588738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06588738.